Table 3 Application of MSCs in treating cGVHD
N | Source of MSCs | Diseases | Age of patients (median/range, years) | Dose of MSCs (cells/kg) | Number of infusions | Median time of MSCs infusion after cGVHD | Outcome | Ref. |
|---|---|---|---|---|---|---|---|---|
23 | Bone marrow | AML: 8 ALL: 4 CML: 6 Other: 5 | 31 [14–51] | 1 × 106 | 3 | – | 1 year CR: 16 1 year PR: 4 1 year minor PR: 3 | [67] |
19 | Bone marrow | AML: 6 ALL: 4 CML: 8 MDS: 1 | 28 [18–39] | 0.6 × 106 | 2 | 35.6 weeks | CR: 10 PR: 4 2 year OS: 77.7% | [69] |
4 | Bone marrow | AML: 2 ALL: 1 MM: 1 | 41 [38–43] | 1–2 × 107 | 4–8 | 17.3 months | OS: 100% | [70] |
14 | Adipose tissue | Lymphomas: 9 Acute leukemias: 4 Myeloma: 1 | 51 [24–60] | 1 × 106 (9) 3 × 106 (5) | – | – | CR: 8 PR: 2 1 year OS: 71.4% Median survival: 45.3 weeks | [71] |